LIVE FOREVER HEALTH™ UNVEILS FULL-STACK HORMONE & TELEMEDICINE FRANCHISE MODEL, PIONEERING LONGEVITY CARE IN ALL 50 STATES
The Specialized Health Leader Offers a Turnkey System for Entrepreneurs to Capitalize on the Booming $27 Billion Hormone Replacement Market with Proven Clinical Protocols and Transparent Pricing.
Introducing the News: The Core Announcement
Read More
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support
BUZZ BOMB™ will power Ashley's elite training, recovery, and lifestyle needs with its best-in-class product
In partnering with Aspire's BUZZ BOMB™ brand, Ashley joins a decorated athlete and fitness trainer roster fueled by the brand's industry-leading commitment to innovation
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure
Partnership strengthens global preparedness against a significant pandemic threat
If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing
Read More
A science-driven 2025 investigation into Synadentix's enzyme technology, hydroxyapatite repair matrix, oral microbiome modulation, and real-world results reported by over 12,000 users
Read MoreSBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in October 2025 with the FDA in support of a possible expedited approval pathway
Read MoreEXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability
EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo
Read MoremNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)
mNEXSPIKE will be available in the European Union, subject to authorization by the European Commission
Read More
12 Month Timeline - How Cannabis Rescheduling Actually Takes Effect
Announcement
President signals intent or issues executive direction
DEA Rulemaking
DEA drafts proposed rule; public notice and comment period
Final DEA Rule
DEA reviews comments and issues final scheduling decision
Federal Register Publication
Legal effective date (often immediate or 30-60 days later)
No Federal Register publication = no change in law
Read More
A data-backed analysis of Sugar Defender, including updated metabolic research, verified user trends, ingredient science, complaint patterns, safety findings, clinical plausibility, and whether this popular blood sugar supplement truly works in 2025.
Read More
A medically guided 2025 investigation into Prostadine's iodine complex, prostate detox claims, urinary-flow results, side effect reports, and what recent consumer data reveals about this trending formula.
Read MoreDriven by rollout of the next-generation Wattbike AIR-PRO across Germany's Fitness First's premium Black Label facilities
Major order follows April's $1M+ order from Woodway for the US market
Read More
More top doctors joined the region's leading physician-owned healthcare group in 2025, increasing patients' access to primary care and medical specialties including family medicine, cardiology, vascular surgery, pain management, rheumatology, and podiatry.
Read MoreConditional approval extended through December 2026 for the treatment of CID in dogs
CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA's June deadline - 51 dogs enrolled to date; ~49 more expected
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome
CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care
Read MoreJaguar CEO Lisa Conte presenting December 10 from 3:25pm - 3:35pm Eastern at the Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID
Company completed meeting with FDA October 2, 2025 for advice on advancing its ongoing placebo-controlled trial of crofelemer in support of possible expedited approval pathway for crofelemer for treatment of MVID
Read More